Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avenue Therapeutics Q2 EPS $(6.43) Misses $(1.05) Estimate

Author: Benzinga Newsdesk | August 09, 2024 04:10pm

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(6.43) per share which missed the analyst consensus estimate of $(1.05) by 512.38 percent. This is a 83.4 percent increase over losses of $(38.74) per share from the same period last year.

Posted In: ATXI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist